7 results
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... Guide Classes ... Diabetes #Mellitus #DM2 ... #pharmacology # ... comparison #table #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
anti-diabetic medications ... kidney), which causes ... SGLT2 #Inhibitors #Pharmacology ... #Medications #DM2 ... #Diabetes #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... not definitively cause ... /effect) • Saxagliptin ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... not definitively cause ... /effect) • May ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
commonly used medications ... to the incretin effect ... GLP1 #Agonists #Pharmacology ... Dosing #Diabetes #DM2 ... #Endocrinology
Pituitary Mass Effects - Pathogenesis and Clinical Findings
 • Pituitary turnors are almost always a benign
affect approximately ... For pituitary masses ... targeted with medication ... #SideEffects #endocrinology ... mnemonic #GLFTAP #pathophysiology
Acromegaly - Diagnosis and Management Summary - GrepMed Handbook 

Clinical Presentation: 
 • Classic Acromegaly: frontal
malignancy Pathophysiology ... Pegvisomant) ± D2 ... or refractory cases ... Diagnosis #Management #Endocrinology ... #Treatment #Pathophysiology